HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
Portfolio Pulse from
HOOKIPA Pharma's eseba-vec, in combination with pembrolizumab, showed promising results in a Phase 2 trial, achieving a 52% overall response rate in patients with PD-L1 CPS>20. The trial also reported encouraging progression-free survival and overall survival data, with a strong T cell response and good safety profile.
November 11, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HOOKIPA Pharma's eseba-vec demonstrated a 52% ORR in a Phase 2 trial with pembrolizumab, showing potential for strong clinical outcomes and safety, which could positively impact the stock.
The positive trial results for eseba-vec, especially the high ORR and good safety profile, suggest potential for future success and market approval, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100